Once-a-Day Trazodone in the Treatment of Depression in Routine
Clinical Practice

J 2018

Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice

ČEŠKOVÁ, Eva, M. ŠEDOVÁ, R. KELLNEROVA and Olga STAROBOVÁ

Basic information

Original name

Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice

Authors

ČEŠKOVÁ, Eva (203 Czech Republic, guarantor, belonging to the institution), M. ŠEDOVÁ (203 Czech Republic), R. KELLNEROVA (203 Czech Republic) and Olga STAROBOVÁ (203 Czech Republic, belonging to the institution)

Edition

PHARMACOLOGY, BASEL, KARGER, 2018, 0031-7012

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.615

RIV identification code

RIV/00216224:14740/18:00104336

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.1159/000492079

UT WoS

000444753700012

Keywords in English

Trazodone; Depression; Clinical practice; Treatment-resistant depression; Individualized treatment; Multimodal antidepressant

Abstract

V originále

Objective: The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a day trazodone tablets (Trittico Prolong (R) 300 mg) in patients with moderate to severe depression in routine clinical practice. Methods: Men and women >= 18 years old with Montgomery-Asberg Depression Rating Scale (MADRS) scores >21 and Clinical Global Impression - Severity (CGI/S) >= 4 were included in this post-authorization, non-interventional, observational prospective safety study, conducted in 8 psychiatric centers in the Czech Republic. The acute treatment phase lasted 5 weeks: 1 week of titration and 4 weeks of full-dose treatment. Patients had follow-up visits 9 and 21 weeks after commencing treatment. Results: Overall, 85 patients were enrolled in the study, of which 80 completed the acute treatment of 5 weeks. There were significant decreases in the overall MADRS score from the baseline mean value of 27.4-21.2 at week 1 (p < 0.001), and a further decrease to 7.9 at week 5 (p < 0.001). The severity of depression according to CGI/S gradually declined. Most patients reported improvement after 6 days of trazodone treatment. The most frequent adverse drug reactions (ADRs) reported were somnolence and fatigue. Conclusions: Trazodone, in the new extended-release formulation, had very good effects in clinical practice, both in previously untreated depressive episodes and in episodes not responsive to previous antidepressive therapy. (C) 2018 S. Karger AG, Basel

Citovat

ČEŠKOVÁ, Eva, M. ŠEDOVÁ, R. KELLNEROVA and Olga STAROBOVÁ. Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice. PHARMACOLOGY. BASEL: KARGER, 2018, vol. 102, 3-4, p. 206-212. ISSN 0031-7012. Available from: https://dx.doi.org/10.1159/000492079.

@article{1461578,
   author = {Češková, Eva and Šedová, M. and Kellnerova, R. and Starobová, Olga},
   article_location = {BASEL},
   article_number = {3-4},
   doi = {http://dx.doi.org/10.1159/000492079},
   keywords = {Trazodone; Depression; Clinical practice; Treatment-resistant depression; Individualized treatment; Multimodal antidepressant},
   language = {eng},
   issn = {0031-7012},
   journal = {PHARMACOLOGY},
   title = {Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice},
   url = {https://www.karger.com/Article/FullText/492079},
   volume = {102},
   year = {2018}
}

TY  - JOUR
ID  - 1461578
AU  - Češková, Eva - Šedová, M. - Kellnerova, R. - Starobová, Olga
PY  - 2018
TI  - Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice
JF  - PHARMACOLOGY
VL  - 102
IS  - 3-4
SP  - 206-212
EP  - 206-212
PB  - KARGER
SN  - 00317012
KW  - Trazodone
KW  - Depression
KW  - Clinical practice
KW  - Treatment-resistant depression
KW  - Individualized treatment
KW  - Multimodal antidepressant
UR  - https://www.karger.com/Article/FullText/492079
N2  - Objective: The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a day trazodone tablets (Trittico Prolong (R) 300 mg) in patients with moderate to severe depression in routine clinical practice. Methods: Men and women >= 18 years old with Montgomery-Asberg Depression Rating Scale (MADRS) scores >21 and Clinical Global Impression - Severity (CGI/S) >= 4 were included in this post-authorization, non-interventional, observational prospective safety study, conducted in 8 psychiatric centers in the Czech Republic. The acute treatment phase lasted 5 weeks: 1 week of titration and 4 weeks of full-dose treatment. Patients had follow-up visits 9 and 21 weeks after commencing treatment. Results: Overall, 85 patients were enrolled in the study, of which 80 completed the acute treatment of 5 weeks. There were significant decreases in the overall MADRS score from the baseline mean value of 27.4-21.2 at week 1 (p < 0.001), and a further decrease to 7.9 at week 5 (p < 0.001). The severity of depression according to CGI/S gradually declined. Most patients reported improvement after 6 days of trazodone treatment. The most frequent adverse drug reactions (ADRs) reported were somnolence and fatigue. Conclusions: Trazodone, in the new extended-release formulation, had very good effects in clinical practice, both in previously untreated depressive episodes and in episodes not responsive to previous antidepressive therapy. (C) 2018 S. Karger AG, Basel
ER  -

ČEŠKOVÁ, Eva, M. ŠEDOVÁ, R. KELLNEROVA and Olga STAROBOVÁ. Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice. \textit{PHARMACOLOGY}. BASEL: KARGER, 2018, vol.~102, 3-4, p.~206-212. ISSN~0031-7012. Available from: https://dx.doi.org/10.1159/000492079.

Detailed Information on Publication Record